+91 80 2808 2808

Biocon’s Liraglutide (gSaxenda®) Receive Approval from MHRA

  • Posted by: BIOCON



“Biocon Limited, through its European partner, Zentiva, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (gSaxenda®) in a 6mg/ml solution for injection in pre-filled pen, used in the treatment of Weight Management as an adjunct to a reduced-calorie diet and increased physical activity.

This is further to our previous intimation of 27th March, 2024, informing that approval was received from the MHRA for Liraglutide (gVicotza®), used in the treatment of Type 2 Diabetes Mellitus, filed through Zentiva.

The approvals will further strengthen Biocon’s portfolio of vertically integrated, complex drug products.”

Author: BIOCON
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>